Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage progr... Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.365 | -13.36996337 | 2.73 | 2.84 | 2.365 | 883975 | 2.73143786 | CS |
4 | -0.265 | -10.0760456274 | 2.63 | 2.84 | 2.365 | 1207282 | 2.57053006 | CS |
12 | -0.435 | -15.5357142857 | 2.8 | 3.305 | 2.365 | 1376469 | 2.79350121 | CS |
26 | -0.355 | -13.0514705882 | 2.72 | 3.45 | 2.33 | 1762812 | 2.8255323 | CS |
52 | 0.275 | 13.1578947368 | 2.09 | 3.45 | 1.64 | 1591901 | 2.57024732 | CS |
156 | -10.285 | -81.3043478261 | 12.65 | 14.425 | 1.51 | 1063895 | 3.81041601 | CS |
260 | -13.535 | -85.1257861635 | 15.9 | 24.47 | 1.51 | 973719 | 4.67632519 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions